This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Hospira's TheraDocâ¿¢ Infection Control Assistant Ranked #1 In Its Category In The Latest "Best In KLAS" Report

LAKE FOREST, Ill., Jan. 23, 2013 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced that its TheraDoc™ Infection Control Assistant™ has been ranked as the top product in the Infection Control & Monitoring software category in the recently released Best in KLAS Awards 2012: Software and Services Report (more information available at www.theradoc.com). The full report is available at www.KLASresearch.com. The rankings are based on data from customer surveys of North American hospital and clinic executives, administrators, physicians, nurses, clinicians, and other directors and managers interacting with healthcare equipment and infrastructure solutions.

TheraDoc Infection Control Assistant scored the highest overall performance rating in KLAS' Infection Control & Monitoring market segment, demonstrating excellence and leadership in serving customers and meeting their expectations. TheraDoc also received the highest product quality rating in its category, and the highest customer willingness to repurchase the software again (95 percent). [1]

"Hospira is honored that TheraDoc has been recognized for excellence in infection monitoring and surveillance software," said France Pitera, vice president, Clinical Information Technology, Hospira. "This recognition is very meaningful since it comes as a direct result of feedback from TheraDoc users. This close working relationship with our users is one key reason why 100 percent of the more than 600 hospitals and healthcare facilities nationwide that have acquired TheraDoc still retain the system today.*"

The TheraDoc clinical surveillance system helps infection preventionists tackle many of their most significant challenges, including time spent on regulatory reporting, time to identification of healthcare-associated infections (HAIs), time to isolation of patients with infectious diseases and tracking of organism resistance.

"After a thorough review of available systems, we chose TheraDoc to support our Infection Prevention program," says Peggy Thompson, R.N., B.S.N., C.I.C., director of Infection Prevention at Tampa General Hospital in Florida. "It has proven to be an invaluable tool in the ever-changing world of infections and regulatory requirements. TheraDoc staff is receptive and incorporates changes based on feedback from their customers." 

The TheraDoc Infection Control Assistant provides infection preventionists with real-time (a matter of seconds) information needed to make a valid identification of infections, while leaving final determination in the hands of infection preventionists. The Infection Control Assistant also delivers powerful tools enabling infection preventionists to configure workflow to their unique needs, develop their own alerts, select from a large library of existing alerts and automate creation of reports for the National Healthcare Safety Network.

Stock quotes in this article: HSP 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs